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Background: Although more than 100 non-HLA variants have been tested for associations with juvenile idiopathic
arthritis (JIA) in candidate gene studies, only a few have been replicated. We sought to replicate reported
associations of single nucleotide polymorphisms (SNPs) in the PTPN22, TNFA and MIF genes in a well-characterized
cohort of children with JIA.
Methods: We genotyped and analyzed 4 SNPs in 3 genes: PTPN22 C1858T (rs2476601), TNFA G-308A, G-238A
(rs1800629, rs361525) and MIF G-173C (rs755622) in 647 JIA cases and 751 healthy controls. We tested for
association between each variant and JIA as well as JIA subtypes. We adjusted for multiple testing using
permutation procedures. We also performed a meta-analysis that combined our results with published results from
JIA association studies.
Results: While the PTPN22 variant showed only modest association with JIA (OR = 1.29, p = 0.0309), it demonstrated
a stronger association with the RF-positive polyarticular JIA subtype (OR = 2.12, p = 0.0041). The MIF variant was not
associated with the JIA as a whole or with any subtype. The TNFA-238A variant was associated with JIA as a whole
(OR 0.66, p = 0.0265), and demonstrated a stronger association with oligoarticular JIA (OR 0.33, p = 0.0006) that was
significant after correction for multiple testing. TNFA-308A was not associated with JIA, but was nominally associated
with systemic JIA (OR = 0.33, p = 0.0089) and enthesitis-related JIA (OR = 0.40, p = 0.0144). Meta-analyses confirmed
significant associations between JIA and PTPN22 (OR 1.44, p <0.0001) and TNFA-238A (OR 0.69, p < 0.0086) variants.
Subtype meta-analyses of the PTPN22 variant revealed associations between RF-positive, RF-negative, and oligoarticular
JIA, that remained significant after multiple hypothesis correction (p < 0.0005, p = 0.0007, and p < 0.0005, respectively).
Conclusions: We have confirmed associations between JIA and PTPN22 and TNFA G-308A. By performing subtype
analyses, we discovered a statistically-significant association between the TNFA-238A variant and oligoarticular JIA. Our
meta-analyses confirm the associations between TNFA-238A and JIA, and show that PTPN22 C1858T is associated with
JIA as well as with RF-positive, RF-negative and oligoarticular JIA.
Keywords: Genetics, Juvenile idiopathic arthritis, Association, Replication* Correspondence: sprahal@emory.edu
†Equal contributors
1Departments of Pediatrics, Emory University School of Medicine, Atlanta, GA,
USA
2Department of Human Genetics, Emory University School of Medicine,
Atlanta, GA, USA
Full list of author information is available at the end of the article
© 2013 Kaalla et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kaalla et al. Pediatric Rheumatology 2013, 11:40 Page 2 of 8
http://www.ped-rheum.com/content/11/1/40Background
Juvenile idiopathic arthritis (JIA) refers to a collection of
chronic autoimmune arthropathies in children. Although
the etiology of JIA is complex, substantial evidence
supports the importance of genetic factors in susceptibility
to JIA [1-3]. While associations between JIA and variants
in HLA are well established, non-HLA genetic variants
also play a role in JIA susceptibility, and have increasingly
been identified by genome-wide and candidate gene studies
[4-6]. However, candidate-gene association studies of
non-HLA variants in JIA have led to inconsistent results.
Of nearly 100 non-HLA polymorphisms tested for associa-
tions with JIA by candidate gene studies, only a handful of
associations have been replicated in independent cohorts
[2,5,7,8]. More recently, the International JIA Immunochip
consortium has confirmed many of the genetic associations
and also identified several new loci with genome-wide
evidence for association [9].
In previous non-HLA genetic association studies, a
functional variant at PTPN22 (C1858T) has been con-
sistently associated with JIA [6,10-12]. Variants at MIF
(G-173C) and TNFA (G-308A, G-238A) genes have also
been associated with JIA, although some of the studies
show mixed results [13-21]. The reasons for non-
replication are myriad, but chief among them is inad-
equate power due to small cohorts. One way to overcome
this limitation is to perform meta-analyses of published
studies. Meta-analyses have confirmed associations between
JIA and genetic variants in STAT4, TNFAIP3, IL2RA, and
CCR5, and have failed to find an association with CTLA4
variants [7,22,23]. Our objectives were to test previously
associated variants at the TNFA and MIF loci in an inde-
pendent JIA cohort and then to combine these results
with published results in a meta-analysis. Furthermore,
since prior studies of the PTPN22 variant have investigated
combined JIA cohorts, we sought to investigate associa-
tions between JIA categories and the PTPN22 variant by
meta-analysis.
Methods
Cases were 647 children with JIA from Pediatric Rheuma-
tology clinics at the University of Utah (N = 437 cases, 750
controls) and Emory University (N = 210 cases). Patients
were diagnosed according to the ILAR criteria [24]. The
median age of onset was 5.8 years, and 67% of the cases
were female. There were 50 children with systemic JIA, 48
with rheumatoid factor (RF)-positive polyarticular JIA,
159 with RF-negative polyarticular JIA, 58 with enthesitis-
related arthritis (ERA), 287 with oligoarticular JIA, and 45
with other categories. Controls were 751 healthy adults
(59% female) screened for several common autoimmune
diseases and ascertained from the same geographic region
as the Utah cases. Only subjects of self-reported Northern
European ancestry were included in this study. Aquestionnaire was used to screen controls for autoimmune
disorders. Controls who reported an autoimmune disorder
were excluded. Subjects were enrolled under protocols
approved by the Institutional Review Boards at the Univer-
sity of Utah and Emory University.
Genotyping
DNA was isolated from peripheral blood using the Puregene
DNA purification kit from Qiagen (Valencia, CA). Subjects
were genotyped for four SNPs in three loci: rs2476601
(C1858T) in the PTPN22 locus, rs1800629 (G-308A)
and rs361525 (G-238A) in the TNFA locus and rs755622
(G-173C) in the MIF locus. These variants were chosen
because of their reported associations with JIA in more
than one cohort based on a review of published literature
[2,6,10-12,14,16-18,25-31]. Genotyping of cases and con-
trols was performed using Taqman pre-designed SNP
genotyping assays (Applied Biosystems, Foster City, CA)
according to the manufacturer’s protocols. To ensure
quality control, ~3% of the samples were genotyped in
duplicate to ensure accuracy and were found to be
concordant. DNA samples with low genotyping success
were removed from analyses.
Statistical analysis
Prior to association analysis, we first tested whether each
variant was in Hardy-Weinberg equilibrium (HWE) in
controls. We then tested for association between each
variant and disease outcome using a logistic regression
model assuming an additive model of allelic effect and
adjusting for gender. From such models, we calculated
allelic odds ratios (OR) and 95% confidence intervals
(95% CI) that were adjusted for gender. Since these variants
have been previously implicated in susceptibility to JIA
and other autoimmune disorders, we considered JIA to be
the primary disease phenotype. However, since JIA is a
collection of several heterogeneous subtypes, we repeated
the analyses for specific JIA subtypes based on ILAR
criteria. Since each of these variants has been previously
implicated as being associated with JIA, we initially focused
on nominal significance (p < 0.05) but subsequently ad-
justed for multiple comparisons using a permutation
procedure. Our permutation procedure generated 1000
datasets under the null hypothesis of no association
between JIA and genotype by repeatedly shuffling the
vector of genotypes for each subject in the dataset.
This type of permutation procedure preserves both the
linkage disequilibrium among variants and the known
effects of gender on JIA. We carried out all analyses using
the R programming language [32].
As we studied variants previously investigated for
association with JIA, we performed a meta- analysis of
these variants that combined our study with published
case-control association studies of JIA (identified using
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from these studies, we performed meta-analyses of
PTPN22, TNFA and MIF associations with JIA using a
fixed-effects model that weighted studies by number of
subjects. We established significance using Cochran-
Mantel-Haenszel tests. We used Cochran’s Q test to
assess heterogeneity among studies, with a significance
level set at p < 0.10, as is recommended for Cochran’s Q
test [33,34]. When we identified heterogeneity between
studies, we repeated the analyses after removing the study
responsible for the heterogeneity. As an alternate analysis,
we performed all the meta-analyses using an unconditional
generalized linear mixed-effects model, which allowed for
random study effects. We performed the meta- analyses
using the R package “metafor” [35].
Results
We found that all four SNPs were in approximate HWE in
our controls, using the Bonferroni-adjusted alpha threshold
of 0.0125. In our cohort, we removed 1 of the 647 cases
missing gender information. Furthermore, we found
that 17 individuals were missing genotype data at MIF
genotypes, 28 were missing PTPN22, 10 were missing
TNFA238, and 40 were missing TNFA308 yielding geno-
typing success rates ranging between 97.2% to 99.3%.
Using logistic regression, we observed that the PTPN22
1858 T variant showed a nominal association in our JIA
cohort (OR = 1.29, p = 0.0309) (Table 1). After stratifica-
tion by subtype, we observed the variant was nominally
associated with two subgroups: those with RF- positive
polyarticular JIA (OR 2.12; p = 0.0041) and oligoarticular
JIA (OR = 1.35, p = 0.0400) (Table 2).
The PTPN22 variant has been investigated for an asso-
ciation with JIA in seven other case-control comparisons
(Table 3) [6,8,10-12,25,26]. (Some of our subjects were
included in a replication study of several autoimmunity
associated variants in JIA [6]. In order to avoid duplication,
the replication cohort used in the study by Thompson
et al. was not included in our meta-analysis). Subjects in
the studies included in our meta-analysis were of European
ancestry. The pooled meta-analysis confirmed a strong
association between JIA and PTPN22 with an OR of
1.44 (95% CI [1.31, 1.60]), p < 0.0001 (Figure 1, Table 4).
When all seven studies plus our data were included,Table 1 Case-control analysis of PTPN22, TNFA and MIF varia
Cases
Variant # Cases MAF # Cont
PTPN22 C1858T 636 0.13 733
MIFG-173C 638 0.18 742
TNFA G-238A 638 0.04 749
TNFA G-308A 628 0.14 729Cochran’s Q test for heterogeneity was not significant
at the p = 0.10 threshold (p = 0.11).
Of the seven studies, only Hinks et al. study reported
data by subtype [10]. We performed a pooled subtype
meta-analysis using our data and data from Hinks et al.
The meta-analysis confirmed findings from our cohort:
the variant was significantly associated with RF-positive,
RF-negative, and oligoarticular JIA (p < 0.0005, p = 0.0007
and p < 0.0005, respectively) (Table 5). Findings remained
significant after correction for multiple hypothesis testing.
Systemic JIA and ERA were not significantly associated
with PTPN22.
We observed no association between the MIF variant in
our JIA cohort as a whole (OR 1.06, 95% CI [0.88-1.29],
nor after stratification by subtype (Tables 1 and 2). The
MIF variant has been investigated for an association with
JIA in three other case-control comparisons, all of which
examined European populations (Table 3) [14,18,31]. The
meta-analysis of the three previous studies and our data
demonstrated (Figure 1) an association between JIA and
MIFG-173C (OR 1.26, 95% CI [1.09, 1.45]; p = 0.0014).
Cochran’s test for heterogeneity was significant (p = 0.04),
however, because the Donn et al. study including subjects
from the United Kingdom [21] demonstrated a much
stronger association between MIF and JIA than the other
studies (Table 3). After removing the study by Donn et al.
from the analysis, we found the resulting association
between MIF and JIA to be negligible (OR 1.12, 95% CI
[0.96, 1.32], p = 0.15) (Table 4), suggesting that the initial
association was driven by the Donn et al. study. Since the
Hinks et al. [10] and Zeggini et al. [30] studies represent
work from the same Manchester group, we were con-
cerned that these studies may also lead to heterogeneity in
our meta-analyses. Therefore, we tested for effect of the
PTPN22 and the TNFA variants, and excluded the Hinks
and Zeggini results. Although the magnitude of the odds
ratios for the three tests decreased with the reduced
sample, inference for all three associations did not change.
Additionally, we were concerned that removing apparently
heterogeneous studies was too conservative an approach;
therefore, we re-ran meta-analyses using a generalized
linear mixed-effects model with random study effects.
Results of the mixed-effects models can be seen in the
Additional file 1: Table S1. Results were comparable tonts and JIA
Controls
rols MAF OR (95% CI) p-value
0.11 1.29 (1.02-1.62) 0.0309
0.17 1.06 (0.88-1.29) 0.5353
0.06 0.66 (0.46, 0.95) 0.0265
0.17 0.82 (0.66, 1.01) 0.0574
Table 2 Results of case-control association of PTPN22, MIF and TNFA variants among JIA sub-phenotypes
PTPN22 MIF TNFA G-238A TNFA G-308A
Subtype # Cases OR (95% CI) # Cases OR (95% CI) # Cases OR (95% CI) # Cases OR (95% CI)
Systemic 50 1.06 (0.53, 1.91) 49 1.53 (0.93, 2.45) 50 1.69 (0.76, 3.36) 50 0.33 (0.13, 0.69)4
RF-Positive 48 2.12 (1.24, 3.49)1 47 1.06 (0.60, 1.75) 48 * 47 0.98 (0.54, 1.66)
RF-Negative 154 1.09 (0.74, 1.57) 158 0.86 (0.61, 1.19) 157 1.14 (0.67, 1.86) 156 0.85 (0.60, 1.18)
ERA 55 1.09 (0.55, 1.97) 56 1.23 (0.74, 1.98) 56 0.94 (0.35, 2.06) 56 0.40 (0.18, 0.78)5
Oligoarticular 284 1.35 (1.01, 1.80)2 283 1.06 (0.83, 1.36) 284 0.33 (0.16, 0.59)3 276 0.96 (0.73, 1.25)
1 p = 0.0041; 2 p = 0.0400; 3 p = 0.0006; 4 p = 0.0089; 5 p = 0.0144; Statistically significant results are bolded. * Represents an analysis that was not conducted due
to small cell size.
Table 3 Studies included in meta-analyses
Cases Controls
Gene Author Ref number Country Publication year # Cases MAF # Controls MAF
PTPN22 C1858T Seldin et al. [7] Finland 2005 230 0.18 1400 0.15
Hinks et al. [5] UK 2005 661 0.15 595 0.10
Cinek et al. [18] Czech/Azeri 2007 130 0.21 400 0.10
Pazar et al. [19] Hungary 2008 150 0.09 200 0.08
Thompson et al. [4] USA 2010 809 0.14 531 0.09
Ellis [29] Australian 2013 324 0.10 568 0.07
Viken et al. [6] Norway 2005 320 0.16 555 0.12
Kaalla et al. Present USA 637 0.13 733 0.11
MIF G-173C Donn et al.* [16] UK 2002 526 0.19 259 0.11
Miterski et al. [9] Germany 2004 150 0.24 390 0.21
Berdeli et al. [13] Turkey 2006 67 0.13 153 0.10
Kaalla et al. Present USA 639 0.18 742 0.17
TNFA G-238A Ozen et al.* [22] Turkey 2002 51 0.22 93 0.27
Ozen et al.* [22] Czech 2002 159 0.23 100 0.17
Zeggini et al. [23] UK 2002 137 0.03 76 0.09
Miterski et al. [9] Germany 2004 130 0.02 375 0.03
Modesto et al. [20] Spain 2005 55 0.07 59 0.09
Schmeling et al. [11] Germany 2006 228 0.03 196 0.03
Kaalla et al. Present USA 639 0.04 749 0.06
TNFA G-308A Ozen et al.* [22] Turkey 2002 51 0.25 93 0.31
Ozen et al.* [22] Czech 2002 159 0.27 100 0.16
Zeggini et al. [23] UK 2002 138 0.24 75 0.13
Miterski et al. [9] Germany 2004 122 0.17 312 0.16
Modesto et al. [20] Spain 2005 55 0.13 59 0.12
Schubert et al. [12] Germany 2006 86 0.15 270 0.15
Schmeling et al. [11] Germany 2006 228 0.14 196 0.17
Mourao et al. [21] Portugal 2009 115 0.12 118 0.11
Kaalla et al. Present USA 629 0.14 729 0.17
*Bolded studies were removed from analysis due to evidence for heterogeneity, using Cochran’s Q test (p < 0.10 threshold).
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Figure 1 Forest Plots of meta-analyses, including all studies.
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TNFA-238A was associated with JIA in our cohort
(OR 0.66, p = 0.0265) (Table 1). Upon stratifying the
analysis by JIA subtype, we observed the most pronounced
association between TNFA-238A and oligoarticular JIA
(OR 0.33, p = 0.0006); no other subtypes were significantly
associated with this SNP (Table 2). The association
between oligoarticular JIA and TNFA-238A was the
strongest association found in this study and remained
significant after adjusting for multiple hypothesis testing
using permutation resampling (corrected p = 0.0113). While
the TNFA-308A showed no association with the entire JIA
cohort, there was a nominal association between this SNPTable 4 Meta-analysis results for PTPN22, MIF and TNFA varia
Cases
Gene # Cases MAF # C
PTPN22 C1858T All Studies 3261 0.14 4
MIF G-173C Including Donn et al. [16] 1382 0.19 1
Removing Donn et al. 856 0.19 1
TNFA G-238A Including Ozen et al. [22] 1399 0.07 1
Removing Ozen et al. 1189 0.03 1
TNFA G-308A Including Ozen et al. [22] 1583 0.17 1
Removing Ozen et al. 1373 0.15 1and systemic JIA (OR 0.33, p = 0.0089) and ERA (OR 0.40,
p = 0.0144) (Tables 1 and 2).
Five studies have previously investigated the TNFAG-
238A variant [14,16,27,29,30] and seven have investigated
the TNFAG-308A variant [14,16,17,27-30] (Table 3). One
of the studies, by Ozen et al. [29], investigated both TNFA
variants in Turkish and Czech cases and controls; the
others studied Western European populations [29]. The
minor allele frequencies (MAF) reported in Ozen et al.
differed widely from the other studies: MAF for TNFAG-
238A in Ozen et al.’s sample was 0.27 (vs. 0.03 for other
studies) and MAF was 0.31 (vs. 0.11) for TNFA G-308A
(Table 3). Including data from Ozen et al. in the meta-
analysis (Figure 1) resulted in significant evidence fornts and JIA
Controls
ontrols MAF OR (95% CI) p-value Data sources
982 0.11 1.44 (1.31, 1.60) <0.0001 4-7, 18,19, 29
544 0.17 1.26 (1.09, 1.45) 0.0356 9, 13, 16
285 0.18 1.12 (0.96, 1.32) 0.1548
648 0.07 0.84 (0.68, 1.04) 0.1033 9, 11, 20, 22, 23
455 0.04 0.69 (0.52, 0.91) 0.0086
952 0.16 1.01 (0.88, 1.15) 0.925 9, 11, 12, 20-23
759 0.16 0.95 (0.83, 1.10) 0.5137
Table 5 Meta-Analysis results for PTPN22 C1858T subtypes: combining Hinks et al. [5] data with data from our cohort
Hinks et al. [5] Kaalla et al. (Present) Combined
Category Size MAF OR (95% CI) Size MAF OR (95% CI) OR (95% CI) p-value
Systemic 118 0.09 0.89 (0.55, 1.44) 50 0.11 1.05 (0.55, 2.01) 0.94 (0.64, 1.39) 0.7675
RF-Positive 35 0.17 1.79 (0.94, 3.43) 48 0.21 2.24 (1.33, 3.77) 2.05 (1.37, 3.77) <0.0005
RF-Negative 135 0.2 2.12 (1.49, 3.02) 154 0.12 1.13 (0.77, 1.66) 1.56 (1.21, 2.02) 0.0007
ERA 48 0.14 1.36 (0.74, 2.51) 55 0.11 1.04 (0.56, 1.94) 1.19 (0.77, 1.84) 0.4431
Oligoarticular 276 0.15 1.56 (1.16, 2.10) 284 0.14 1.36 (1.01, 1.82) 1.45 (1.18, 1.79) <0.0005
Controls 595 0.1 NA 733 0.11 NA NA NA
PTPN22 allele frequency and odds ratios from Hinks et al. [5] and Kaalla et al. (Present) divided by five JIA categories. No covariates were included in the analyses.
Pooled data significant at the α = 0.05 threshold level is bolded.
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TNFAG-308A, respectively), and hence the meta-analyses
were repeated after excluding the study (Table 4) and by
using a random effects model (Additional file 1: Table S1).
There was a lack of association between JIA and either
TNFA variant when we included all studies; however, after
excluding the Ozen et al. study, we identified an associ-
ation between TNFA-238A and JIA (OR 0.69, 95% CI
[0.52, 0.91], p = 0.0086) (Table 4). We observed no associ-
ation between TNFA-308A and JIA (Table 4, Figure 1).
Discussion
JIA is a complex trait believed to be influenced by both
genetic and environmental factors [1]. Convincing associa-
tions between polymorphisms in the genes encoding the
human leukocyte antigens (HLA) and JIA have been
reported in multiple cohorts. HLA-DR is estimated to
account for only ~17% of susceptibility to JIA, suggesting
that non-HLA loci contribute substantially to JIA suscep-
tibility [36]. To date, a few non-HLA variants have been
demonstrated to have replicable associations. A compre-
hensive review of non-HLA associations suggested that
most studies are underpowered and very few positive as-
sociations are replicated [2]. A handful of genes, including
PTPN22, TNFAIP3, STAT4, PTPN2, and CCR5, have shown
replicated associations [5,6,22,37], but many other associa-
tions have not been formally replicated. One strategy to
improve power and develop a more accurate estimate of
effect size in genetic associations is to perform meta-
analysis of published studies to validate previous asso-
ciations, as we did in this study. Our meta-analysis,
with 3200 cases with JIA and over 5000 controls confirms
a statistically significant association between PTPN22
and JIA.
The gene TNFA, which encodes the proinflammatory
cytokine TNF-α, is located in the MHC region on
chromosome 6 and has been implicated in susceptibility
to a number of rheumatic diseases, including rheumatoid
arthritis. TNFA variants have been investigated for an
association with JIA in a variety of studies. While associ-
ations between microsatellite polymorphisms in TNFAand different subtypes of JIA have been reported in various
studies [13-15], investigations of two functional SNPs have
yielded mixed results. We were able to find an association
between the G-238A variant and oligoarticular JIA. The
meta-analysis also suggests an association. Since the TNFA
locus is in the MHC region, the associations observed
could reflect linkage disequilibrium with HLA variants.
Our combined JIA cohort, while larger than several
previously published cohorts, was still underpowered to
detect small effects. For our primary analyses, we analyzed
the JIA cohort as a whole, given the recent demonstration
that clinically distinct autoimmune disorders share com-
mon susceptibility loci [38-40]. Since JIA is a collection
of heterogeneous subtypes, we also performed stratified
analyses of JIA sub-phenotypes in our data, but our power
to detect associations with some of the less common JIA
categories was low. Only one other study, Hinks et al.,
provided genotype data by category [10]. In a pooled
analysis with their data, the importance of analysis by
categories was emphasized; the strongest associations we
found were in JIA subphenotypes, rather than the global
JIA phenotype. Analyzing by subphenotype therefore
appears to be a valuable procedure, as it reduces the
negative impact of phenotypic and genetic heterogeneity.
A limitation with all candidate gene studies is the poten-
tial of population stratification. While we attempted to
minimize the effects of stratification by selecting only
self-reporting European ancestry for our cohort and in-
cluding only studies from Northern European samples in
our meta-analysis, we acknowledge that this effect could
perhaps influence our findings. We were also concerned
about site heterogeneity in our study, since controls were
obtained from Utah, while cases were obtained from both
Utah and Georgia. Therefore, we re-ran our analyses with
only Utah cases (N = 432) and controls (N = 750). Although
the standard deviation increased with decreasing sample
sizes, point estimates remained approximately identical for
all analyses, indicating that between -site heterogeneity
does not to appear to be a concern in our study. Results of
these analyses can be seen in Additional file 2: Table S2
and Additional file 3: Table S3.
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have been published recently [41,42]. Lee et al. found no
association between JIA and TNFA G-238A and TNFA
G-308A variants among European subjects [41]. In con-
trast, our results do support an association between
TNFA G-238A and JIA, and in particular oligoarticular
JIA (significant after correction for multiple testing). Our
meta-analysis also supported an association between this
variant and JIA. As previously reported by Lee et al., we
also did not find an association between JIA and TNFA
G-308A [41]. Based on their meta-analysis, Lee et al.
concluded there was association between PTPN22 C1858T
and MIF C-173G variants [42]. While we confirmed the
association between PTPN22 C1858T and JIA, we did not
confirm the association with the MIF C-173G variant.
There are several possible explanations for the discrepan-
cies observed. First there might be true differences between
the different populations being evaluated. Second, by
the addition of almost 1400 subjects, our meta-analysis
benefited from improved power. Third, the studies included
in the meta-analyses varied somewhat. For instance,
Lee et al. chose to include a study by Hohler et al.,
which investigated an association between TNFA G-238A
and juvenile psoriatic arthritis and psoriasis [43]. We did
not include the study by Hohler et al in our meta-analysis,
since the subjects in their study were all adults, with
“juvenile onset” having been defined as onset before
the age of 40. In addition other subjects in that study had
psoriasis without arthritis. Thus we felt their inclusion of
these subjects in a meta-analysis of JIA was inappropriate.
Finally, it should be noted that the minor allele frequen-
cies extracted by Lee et al. for PTPN22 C1858T from the
study by Thompson et al [6]. were substantially different
than the actual frequencies reported in the original paper.
Whereas Thompson et al. reported the case/control MAF
for PTPN22 C1858T to be 0.143/0.094 and 0.149/0.095
for the initial and replication cohorts respectively (Tables 2
and 3 in Thompson et al. [6]), Lee et al. report these to be
0.249/0.193 and 0.252/0.204 for the same cohorts (Table 1,
Lee et al. [42]).
Conclusions
In conclusion, our study provides convincing, replicated
evidence that PTPN22 is associated with JIA. Our study
also demonstrates the increased power of meta-analysis,
and demonstrates that the PTPN22 C1858T variant is
particularly associated with RF-negative, RF-positive and
oligoarticular JIA categories, but not with ERA or systemic
JIA. PTPN22 C1858T variant has been identified as an
underlying risk factor for several different autoimmune
phenotypes [38,44,45]. Our finding supports the notion
that clinically distinct autoimmune phenotypes can share
common susceptibility factors, offering a potential target
for further research and possible therapy. Our study alsodemonstrates an association between oligoarticular JIA
and TNFA-238A, supporting future investigations of the
TNF-α pathway in JIA.
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